Omar Algabbass

- leading KSA IBD Team to launch Tremfya and expand Stelara in Saudi Market.

- Review and support access and marketing strategies and execution.

- Measure market potential top to bottom and bottom up.

- Hire, Coach and Motivate sales Team.

- Set Business plan for the coming 5 years.

- Supply and demand review with SC Team.

- handel RFQ, invoicing and deliveries.

- Led WZ IBD Team to expand Stelara business.

- Review and support access and marketing strategies and execution.

- Measure market potential top to bottom and bottom up.

- Hire, Coach and Motivate sales Team.

- Supply and demand review with SC Team.

- Visited key opinion leaders in KSA from MOH and Institution PVT.

- Handeled RFQ, DPO, invoicing, and delivery processes.

- Achived 108% of sales TGT

- Establish MS Team to launch Ponvory in Saudi Market.

- Review and support access and marketing strategies and execution.

- Measure market potential top to bottom and bottom up.

- Hire, Coach and Motivate sales Team.

- Set Business plan for the coming 5 years.

- Supply and demand review with SC Team.

- handel RFQ, invoicing and deliveries.

• Communication ambassador between internal stakeholders (4 therapy area, supply chain, TND Manager, Marketing, and medical) and external stakeholders (MOH medical supplies, NUPCO
  Warehouses, institution Medical supply, chain Pharmacies, Planning,
  purchasing, Tamer, Cigalah, Head of Pharmacies, clinical
  pharmacists and health economics)
• Oversaw operations for Hematology, Oncology, CNS, and Pulmonary Hypertension therapy areas.
• Managed supply, sales, and delivery operations.
• Monitored JNJ portfolio expiry across private, MOH, and institutional sectors.
• Facilitated access of JNJ items in MOH, private, and institution.
• Calculated and submitted TND quantities to ensure accurate inventory management.
• Mentor, coach, and devalop new talant.
• Secured area target achievement for four years in raw.

• Establish SudairPharma concept in the market and Launch Oncology and Hematology portofolio in the WZ zone.
• business expansion in Western and Southern regions, access to MOH, institutions, and PVT.
• Achieved sales of 35 million SAR with collections totalling 23 million SAR.
• Managed end-to-end processes for RFQ, sales, invoicing, delivery, and collections.
• Opened new accounts to increase customer base.
• Collaborated with Bupa Insurance Company to resolve prescription rejection issues.

• visits to medical supplies and finance departments within MOH institutions.
• Resolved all pending Octapharma collection values since 2013 through effective team management.
• Facilitated 63 NUPCO TND CRM submissions for Alsaif items successfully.
• Streamlined RFQ, sales, invoicing, and delivery processes for improved efficiency.
• Expanded client base by introducing Octapharma items to new customers.
• Expiry management.
• mannged clearancs SFDA system.

• Elevate awareness of neuroendocrine tumors and acromegaly in MOH institutions and private in Western and Southern areas.
• Ensure medication availability in hospitals and successfully recruited patients.
• Calculate patient numbers and TND quantities for targeted areas.
  Managed stock efficiently, overseeing DPO and delivery processes.
• Fostered valuable customer engagements.
• Achieved highest patient recruitment growth at 24% over KSA in 2017, and achieved 104% of sales in 2018.

• launch new treatment class SGLT2 in diabites market.
• Visit to Endocrinology, Family Medicine, Pharmacies,Planning, and Purchasing Departments in institutions,
• Effectively promoting and distinguishing Onglyza & Farxiga from competitors to increase patient recruitment and drive sales growth.
• Collaborated with medical supply to calculate TND quantities.
• Demonstrated exceptional sales performance, achieving 153% of sales targets in 2015 and 161% in 2016.